Cell therapies for the central nervous system: How do we identify the best candidates?

Current Opinion in Neurology

Volumn 24, Issue 6, 2011, Pages 570-576

  Noble, Mark ^a   Mayer Pröschel, Margot ^a   Davies, Jeannette E ^b   Davies, Stephen J A ^b   Pröschel, Christoph ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

astrocyte transplantation therapy; cell transplantation therapies; glial restricted precursor cells; glial restricted precursor derived astrocyte; spinal cord injury

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4;

ASTROCYTE; CELL CULTURE; CELL ISOLATION; CELL SELECTION; CENTRAL NERVOUS SYSTEM DISEASE; CONTUSION; GLIA CELL; GLIAL PRECURSOR CELL; HUMAN; NERVE FIBER REGENERATION; NERVE TRANSECTION; NEURAL STEM CELL TRANSPLANTATION; NEUROEPITHELIUM; NONHUMAN; OLFACTORY ENSHEATHING CELL; OLFACTORY EPITHELIUM; OLIGODENDROGLIA; REPRODUCIBILITY; REVIEW; SCHWANN CELL; SPINAL CORD INJURY;

ANIMALS; ASTROCYTES; CELL TRANSPLANTATION; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; REPRODUCIBILITY OF RESULTS; SPINAL CORD INJURIES; TREATMENT OUTCOME;

EID: 81855175971     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32834cd4c9     Document Type: Review

References (63)

1. Allan LE, Petit GH, Brundin P. Cell transplantation in Parkinson's disease: problems and perspectives. Curr Opin Neurol 2010; 23:426-432.
2. Jankovic J. An update on the treatment of Parkinson's disease. Mt Sinai J Med 2006; 73:682-689. (Pubitemid 44110939)
3. Burt RK, Loh Y, Pearce W, et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. J Am Med Assoc 2008; 299:925-936. (Pubitemid 351397068)
4. Burt RK, Testori A, Craig R, et al. Hematopoietic stem cell transplantation for autoimmune diseases: what have we learned? J Autoimmun 2008; 30:116-120.
5. Marmont AM, Burt RK. Hematopoietic stem cell transplantation for systemic lupus erythematosus, the antiphospholipid syndrome and bullous skin diseases. Autoimmunity 2008; 41:639-647.
6. Milanetti F, Abinun M, Voltarelli JC, Burt RK. Autologous hematopoietic stem cell transplantation for childhood autoimmune disease. Pediatr Clin North Am 2010; 57:239-271.
7. Rama P, Bonini S, Lambiase A, et al. Autologous fibrin-cultured limbal stem cells permanently restore the corneal surface of patients with total limbal stem cell deficiency. Transplantation 2001; 72:1478-1485. (Pubitemid 33095504)
8. Rama P, Matuska S, Paganoni G, et al. Limbal stem-cell therapy and long-term corneal regeneration. N Engl J Med 2010; 363:147-155.
9. Groves AK, Barnett SC, Franklin RJ, et al. Repair of demyelinated lesions by transplantation of purified O-2A progenitor cells. Nature 1993; 362:453-455. (Pubitemid 23107369)
10. Mitsui T, Shumsky JS, Lepore AC, et al. Transplantation of neuronal and glial restricted precursors into contused spinal cord improves bladder and motor functions, decreases thermal hypersensitivity, and modifies intraspinal circuitry. J Neurosci 2005; 25:9624-9636. (Pubitemid 41510903)
11. Barnett SC, Riddell JS. Olfactory ensheathing cell transplantation as a strategy for spinal cord repair: what can it achieve? Nat Clin Pract Neurol 2007; 3:152-161. (Pubitemid 46403942)
12. Fortun J, Hill CE, Bunge MB. Combinatorial strategies with Schwann cell transplantation to improve repair of the injured spinal cord. Neurosci Lett 2009; 456:124-132.
13. Goldman SA, WindremMS. Cell replacement therapy in neurological disease. Philos Trans R Soc Lond B Biol Sci 2006; 361:1463-1475. (Pubitemid 44450205)
14. Kan EM, Ling EA, Lu J. Stemcell therapy for spinal cord injury. Curr Med Chem 2010; 17:4492-4510.
15. King-Robson J. Encouraging regeneration in the central nervous system: is there a role for olfactory ensheathing cells? Neurosci Res 2011; 69:263-275.
16. Mackay-Sim A, St John JA. Olfactory ensheathing cells from the nose: clinical application in human spinal cord injuries. Exp Neurol 2011; 229:174-180.
17. Mortazavi MM, Verma K, Tubbs RS, Theodore N. Cellular and paracellular transplants for spinal cord injury: a review of the literature. Childs Nerv Syst 2011; 27:237-243.
18. Radtke C, SasakiM, Lankford KL, et al. Potential of olfactory ensheathing cells for cell-based therapy in spinal cord injury. J Rehabil Res Dev 2008; 45:141-151.
19. Ronaghi M, Erceg S, Moreno-Manzano V, Stojkovic M. Challenges of stemcell therapy for spinal cord injury: human embryonic stem cells, endogenous neural stem cells, or induced pluripotent stem cells? Stem Cells 2010; 28:93-99.
20. Ronsyn MW, Berneman ZN, Van Tendeloo VF, et al. Can cell therapy heal a spinal cord injury? Spinal Cord 2008; 46:532-539.
21. Rossi SL, Keirstead HS. Stem cells and spinal cord regeneration. Curr Opin Biotechnol 2009; 20:552-562.
22. Ruff CA, Fehlings MG. Neural stem cells in regenerative medicine: bridging the gap. Panminerva Med 2010; 52:125-147.
23. Sahni V, Kessler JA. Stem cell therapies for spinal cord injury. Nat Rev Neurol 2010; 6:363-372.
24. Sasaki M, Li B, Lankford KL, et al. Remyelination of the injured spinal cord. Prog Brain Res 2007; 161:419-433. (Pubitemid 47017419)
25. Noble M, Davies JE, Mayer-Proschel M, et al. Precursor cell biology and the development of astrocyte transplantation therapies: lessons from spinal cord injury. Neurotherapeutics 2011; doi:10.1007/s13311-011-0071-z [Epub ahead of print].
26. Lavdas AA, Papastefanaki F, Thomaidou D, Matsas R. Schwann cell transplantation for CNS repair. Curr Med Chem 2008; 15:151-160. (Pubitemid 351234618)
27. Oudega M, Moon LD, de Almeida Leme RJ. Schwann cells for spinal cord repair. Braz J Med Biol Res 2005; 38:825-835. (Pubitemid 40932235)
28. Oudega M, Xu XM. Schwann cell transplantation for repair of the adult spinal cord. J Neurotrauma 2006; 23:453-467. (Pubitemid 43726321)
29. Davies JE, Huang C, Proschel C, et al. Astrocytes derived from glial-restricted precursors promote spinal cord repair. J Biol 2006; 5:7.
30. Davies JE, Prö schel C, Zhang N, et al. Transplanted astrocytes derived from BMP or CNTF treated glial restricted precursors have opposite effects on recovery and allodynia after spinal cord injury. J Biol 2008; 7:e24.
31. Davies SJA, Shih C-H, Noble M, et al. Transplantation of specific human astrocytes promotes functional recovery after spinal cord injury. PLoS One 2011; 6:e17328; doi: 10.1371/journal.pone.0017328.
32. Gregori N, Proschel C, Noble M, Mayer-Prö schel M. The tripotential glialrestricted precursor (GRP) cell and glial development in the spinal cord: generation of bipotential oligodendrocyte-type-2 astrocyte progenitor cells and dorsalventral differences in GRP cell function. J Neurosci 2002; 22:248-256. (Pubitemid 34033502)
33. Noble M, Prö schel C, Mayer-Proschel M. Getting a GR(i)P on oligodendrocyte development. Dev Biol 2004; 265:33-52. (Pubitemid 38028512)
34. Rao M, Mayer-Prö schel M. Glial restricted precursors are derived from multipotent neuroepithelial stem cells. Dev Biol 1997; 188:48-63. (Pubitemid 27360086)
35. Rao M, Noble M, Mayer-Prö schel M. A tripotential glial precursor cell is present in the developing spinal cord. Proc Natl Acad Sci USA 1998; 95:3996-4001. (Pubitemid 28173242)
36. Hill CE, Gensel JC, Tovar CA, et al. Transplantation of glial restricted precursor cells into acute spinal cord contusion injuries. In: Soc Neurosci Abstr 2001, vol. 27. Abstr no. 768.2.
37. Hill CE, Prö schel C, Noble M, et al. Acute transplantation of glial restricted precursor cells into spinal cord contusion injuries: survival, differentiation and effects on lesion environment and axonal regeneration. Exp Neurol 2004; 190:289-310. (Pubitemid 39504988)
38. Nout YS, Culp E, Schmidt MH, et al. Glial restricted precursor cell transplant with cyclic adenosine monophosphate improved some autonomic functions but resulted in a reduced graft size after spinal cord contusion injury in rats. Exp Neurol 2011; 227:159-171.
39. Lu J, Féron F, Mackay-Sim A, Waite PM. Olfactory ensheathing cells promote locomotor recovery after delayed transplantation into transected spinal cord. Brain 2002; 125:14-21. (Pubitemid 34084033)
40. Li S, Strittmatter SM. Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury. J Neurosci 2003; 23:4219-4227. (Pubitemid 36958442)
41. Pearse DD, Pereira FC, Marcillo AE, et al. cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. Nat Med 2004; 10:610-616. (Pubitemid 38796852)
42. Lee SM, Yune TY, Kim SJ, et al. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma 2003; 20:1017-1027. (Pubitemid 37288561)
43. Gorio A, Gokmen N, Erbayraktar S, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 2002; 99:9450-9455. (Pubitemid 34764634)
44. Vitellaro-Zuccarello L, Mazzetti S, Madaschi L, et al. Erythropoietin-mediated preservation of the white matter in rat spinal cord injury. Neuroscience 2007; 144:865-877. (Pubitemid 46013988)
45. Ning B, Zhang A, Song H, et al. Recombinant human erythropoietin prevents motor neuron apoptosis in a rat model of cervical sub-acute spinal cord compression. Neurosci Lett 2011; 490:57-62.
46. Hains BC, Black JA, Waxman SG. Primary cortical motor neurons undergo apoptosis after axotomizing spinal cord injury. J Comp Neurol 2003; 462:328-341. (Pubitemid 36736715)
47. Nielson JL, Strong MK, Steward O. A re-assessment of whether cortical motor neurons die following spinal cord injury. J Comp Neurol 2011; 519:2852-2869.
48. Sharp KG, Flanagan LA, Yee KM, Steward O. A re-assessment of a combinatorial treatment involving Schwann cell transplants and elevation of cyclic AMP on recovery of motor function following thoracic spinal cord injury in rats. Exp Neurol 2010; doi:10.1016/j.expneurol.2010.12.020 [Epub ahead of print].
49. Steward O, Sharp K, SelvanG, et al. A re-assessment of the consequences of delayed transplantation of olfactory lamina propria following complete spinal cord transection in rats. Exp Neurol 2006; 198:483-499.
50. Steward O, Sharp K, Yee KM, Hofstadter M. A re-assessment of the effects of a Nogo-66 receptor antagonist on regenerative growth of axons and locomotor recovery after spinal cord injury in mice. Exp Neurol 2008; 209:446-468.
51. Pinzon A, Marcillo A, Quintana A, et al. A re-assessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model. Brain Res 2008; 1243:146-151.
52. Pinzon A, Marcillo A, Pabon D, et al. A re-assessment of erythropoietin as a neuroprotective agent following rat spinal cord compression or contusion injury. Exp Neurol 2008; 213:129-136.
53. Bonner JF, Blesch A, Neuhuber B, Fischer I. Promoting directional axon growth from neural progenitors grafted into the injured spinal cord. J Neurosci Res 2010; 88:1182-1192.
54. Lepore AC, Fischer I. Lineage-restricted neural precursors survive, migrate, and differentiate following transplantation into the injured adult spinal cord. Exp Neurol 2005; 194:230-242. (Pubitemid 40719758)
55. Jin Y, Neuhuber B, Singh A, et al. Transplantation of human glial restricted progenitors and derived astrocytes into a contusion model of spinal cord injury. J Neurotrauma 2011; 28:579-594.
56. Popovich PG, Gensel JC, Tovar CA. Independent evaluation of the effects of glibenclamide on reducing progressive hemorrhagic necrosis after cervical spinal cord injury. Exp Neurol 2010; doi: 10.1016/j.expneurol.2010.11.016 [Epub ahead of print].
57. Simard JM, TsymbalyukO, Ivanov A, et al. Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP 581 channels mediate progressive hemorrhagic necrosis following spinal cord injury. J Clin Invest 2007; 117:2105-2113. (Pubitemid 47219555)
58. Davies SJ, Field PM, Raisman G. Regeneration of cut adult axons fails even in the presence of continuous aligned glial pathways. Exp Neurol 1996; 142:203-216. (Pubitemid 26414055)
59. Davies SJ, Fitch MT, Memberg SP, et al. Regeneration of adult axons in white matter tracts of the central nervous system. Nature 1997; 390:680-683. (Pubitemid 28016354)
60. Conti A, Miscusi M, Cardali S, et al. Nitric oxide in the injured spinal cord: synthases cross-talk, oxidative stress and inflammation. Brain Res Rev 2007; 54:205-218. (Pubitemid 46498169)
61. Genovese T, Cuzzocrea S. Role of free radicals and poly (ADP-ribose) polymerase-1 in the development of spinal cord injury: new potential therapeutic targets. Curr Med Chem 2008; 15:477-487. (Pubitemid 351472414)
62. Hall ED, Vaishnav RA, Mustafa AG. Antioxidant therapies for traumatic brain injury. Neurotherapeutics 2010; 7:51-61.
63. Michael-Titus AT. Omega-3 fatty acids and neurological injury. Prostaglandins Leukot Essent Fatty Acids 2007; 77:295-300. (Pubitemid 350198867)